Product Description
AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01129193)
Mechanisms of Action: HDAC6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alison Walker
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Neurilemmoma|Meningioma|Acute Myeloid Leukemia|Neuroma, Acoustic|Neurofibromatosis 2|Renal Cell Carcinoma|Neurofibromatoses|Prolymphocytic T-Cell Leukemia|Waldenstrom Macroglobulinemia|Follicular Lymphoma|Prolymphocytic B-Cell Leukemia|Mantle-Cell Lymphoma|Sezary Syndrome|T-Cell Peripheral Lymphoma|Leukemia, Plasma Cell|Kidney Diseases|Burkitt Lymphoma|Sarcoma|Large-Cell Anaplastic Lymphoma|Adult T-Cell Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoproliferative Disorders|B-Cell Marginal Zone Lymphoma|Testicular Cancer|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma|Large-Cell Immunoblastic Lymphoma|Chronic Lymphoid Leukemia|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Intraocular Lymphoma|Lymphomatoid Granulomatosis|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Plasmablastic Lymphoma|Mycosis Fungoides|Prolymphocytic Leukemia|Immunoblastic Lymphadenopathy|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OSU-15004 | P1 |
Completed |
Multiple Myeloma |
2020-11-14 |
|
| 14-078H | P1 |
Terminated |
Neurofibromatoses|Neurofibromatosis 2|Neurilemmoma|Meningioma|Neuroma, Acoustic |
2017-05-30 |
|
| OSU-09102 | P1 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Intraocular Lymphoma|Chronic Lymphoid Leukemia|Adult T-Cell Leukemia-Lymphoma|Waldenstrom Macroglobulinemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Follicular Lymphoma|Burkitt Lymphoma|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Prolymphocytic T-Cell Leukemia|Mycosis Fungoides|T-Cell Peripheral Lymphoma|Multiple Myeloma|Mantle-Cell Lymphoma|Immunoblastic Lymphadenopathy|Diffuse Large B-Cell Lymphoma|Large-Cell Anaplastic Lymphoma|Leukemia, Plasma Cell|Large-Cell Immunoblastic Lymphoma|Prolymphocytic B-Cell Leukemia|Sezary Syndrome|Lymphoproliferative Disorders|Lymphoma, Non-Hodgkin|Lymphomatoid Granulomatosis|T-Cell Cutaneous Lymphoma|Plasmablastic Lymphoma|Testicular Cancer|Prolymphocytic Leukemia|B-Cell Marginal Zone Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2017-01-07 |
|
| MCC-14-10774 | P1 |
Terminated |
Kidney Diseases|Sarcoma|Renal Cell Carcinoma |
2016-11-24 |